$KANT
KINETA, INC./DE

2024 Q1 Form 10-K Financial Statement

#000095017024034676 Filed on March 21, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $5.442M
YoY Change -100.0% -100.0% 178.65%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.680M $2.710M $12.14M
YoY Change -6.12% -146.17% 39.56%
% of Gross Profit
Research & Development $2.726M $1.561M $9.023M
YoY Change -4.12% -94.43% -43.35%
% of Gross Profit
Depreciation & Amortization $0.00 -$1.000K $9.000K
YoY Change -100.0% -97.5% -87.67%
% of Gross Profit
Operating Expenses $6.406M $4.271M $21.17M
YoY Change -5.33% -80.73% -51.33%
Operating Profit -$6.406M -$15.72M
YoY Change -1.23% -62.14%
Interest Expense $42.00K $53.00K $337.0K
YoY Change 82.61% -101.51% -90.98%
% of Operating Profit
Other Income/Expense, Net -$3.843M $1.558M $1.647M
YoY Change -64150.0% -108.42% -107.51%
Pretax Income -$10.25M -$2.660M -$14.08M
YoY Change 58.16% -93.65% -77.82%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$10.24M -$2.654M -$14.10M
YoY Change 58.7% -93.65% -77.76%
Net Earnings / Revenue -259.08%
Basic Earnings Per Share -$0.89 -$1.28
Diluted Earnings Per Share -$0.89 -$0.24 -$1.28
COMMON SHARES
Basic Shares Outstanding 10.96M 10.39M 11.05M
Diluted Shares Outstanding 11.44M 11.05M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.773M $5.783M $5.783M
YoY Change -80.73% -55.85% -55.85%
Cash & Equivalents $1.848M $5.858M
Short-Term Investments
Other Short-Term Assets $387.0K $194.0K $194.0K
YoY Change 29.0% -61.2% -61.2%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $2.160M $5.977M $5.977M
YoY Change -77.43% -56.05% -56.05%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00 $4.304M
YoY Change -100.0% -100.0% 16.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Assets $273.0K $4.304M $4.304M
YoY Change -92.16% 12.23% 13.26%
TOTAL ASSETS
Total Short-Term Assets $2.160M $5.977M $5.977M
Total Long-Term Assets $273.0K $4.304M $4.304M
Total Assets $2.433M $10.28M $10.28M
YoY Change -81.36% -41.03% -40.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.126M $3.694M $3.694M
YoY Change -37.71% -44.33% -44.03%
Accrued Expenses $1.452M $2.211M $2.758M
YoY Change 38.02% -37.31% -37.32%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $629.0K $620.0K $620.0K
YoY Change
Total Short-Term Liabilities $8.526M $7.072M $7.072M
YoY Change -28.71% -38.43% -38.5%
LONG-TERM LIABILITIES
Long-Term Debt $150.0K $159.0K $150.0K
YoY Change -81.25% -80.13% -81.25%
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $150.0K $159.0K $150.0K
YoY Change -86.36% -87.77% -88.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.526M $7.072M $7.072M
Total Long-Term Liabilities $150.0K $159.0K $150.0K
Total Liabilities $8.676M $7.222M $7.391M
YoY Change -33.8% -43.86% -43.15%
SHAREHOLDERS EQUITY
Retained Earnings -$176.0M -$165.8M
YoY Change 11.32% 9.29%
Common Stock $11.00K $10.00K
YoY Change 22.22% 25.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.401M $2.890M $2.890M
YoY Change
Total Liabilities & Shareholders Equity $2.433M $10.28M $10.28M
YoY Change -81.36% -41.03% -40.91%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$10.24M -$2.654M -$14.10M
YoY Change 58.7% -93.65% -77.76%
Depreciation, Depletion And Amortization $0.00 -$1.000K $9.000K
YoY Change -100.0% -97.5% -87.67%
Cash From Operating Activities -$4.011M -$4.079M -$16.21M
YoY Change -18.81% 82.91% -14.82%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $1.000K $331.0K
YoY Change -100.0% -99.99% -96.46%
Cash From Investing Activities $0.00 $1.000K $331.0K
YoY Change -100.0% -99.99% -96.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $8.561M
YoY Change 441.49%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.000K 2.248M 8.468M
YoY Change -99.87% -90.71% -28.29%
NET CHANGE
Cash From Operating Activities -4.011M -4.079M -16.21M
Cash From Investing Activities 0.000 1.000K 331.0K
Cash From Financing Activities 1.000K 2.248M 8.468M
Net Change In Cash -4.010M -1.830M -7.410M
YoY Change 2.69% -106.18% -461.64%
FREE CASH FLOW
Cash From Operating Activities -$4.011M -$4.079M -$16.21M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$4.079M -$16.21M
YoY Change 81.29% -15.14%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001445283
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Registrant Name
EntityRegistrantName
KINETA, INC./DE
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 us-gaap Servicing Asset At Fair Value Other Change In Fair Value Statement Of Income Or Comprehensive Income Extensible Enumeration
ServicingAssetAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense
CY2023Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-37695
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8436652
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
7683 SE 27th Street
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 481
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Mercer Island
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98040
CY2023 dei City Area Code
CityAreaCode
206
CY2023 dei Local Phone Number
LocalPhoneNumber
378-0400
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023 dei Trading Symbol
TradingSymbol
KA
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
10300000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10962460
CY2023 dei Auditor Firm
AuditorFirmId
688
CY2023 dei Auditor Name
AuditorName
Marcum LLP
CY2023 dei Auditor Location
AuditorLocation
New York, New York
CY2023Q4 us-gaap Cash
Cash
5783000
CY2022Q4 us-gaap Cash
Cash
13143000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
75000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
0
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
119000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
457000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
5977000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
13600000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
249000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
472000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1211000
CY2023Q4 ka Rights From Private Placement
RightsFromPrivatePlacement
3832000
CY2022Q4 ka Rights From Private Placement
RightsFromPrivatePlacement
2250000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
0
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
125000
CY2023Q4 us-gaap Assets
Assets
10281000
CY2022Q4 us-gaap Assets
Assets
17435000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3694000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6635000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2211000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3527000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
442000
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
620000
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
547000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
843000
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
0
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
40000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7072000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11487000
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
150000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
748000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
547000
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
0
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
83000
CY2023Q4 us-gaap Liabilities
Liabilities
7222000
CY2022Q4 us-gaap Liabilities
Liabilities
12865000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10397000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10397000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8318000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8318000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
168669000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
156106000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-165789000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-151690000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
2890000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4424000
CY2023Q4 us-gaap Minority Interest
MinorityInterest
169000
CY2022Q4 us-gaap Minority Interest
MinorityInterest
146000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3059000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4570000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10281000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17435000
CY2023 us-gaap Revenues
Revenues
5442000
CY2022 us-gaap Revenues
Revenues
1953000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9023000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15928000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12142000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8696000
CY2023 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
0
CY2022 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
18860000
CY2023 us-gaap Operating Expenses
OperatingExpenses
21165000
CY2022 us-gaap Operating Expenses
OperatingExpenses
43484000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-15723000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-41531000
CY2023 us-gaap Interest Income Other
InterestIncomeOther
325000
CY2022 us-gaap Interest Income Other
InterestIncomeOther
9000
CY2023 ka Interest Expense Related Parties
InterestExpenseRelatedParties
0
CY2022 ka Interest Expense Related Parties
InterestExpenseRelatedParties
1659000
CY2023 us-gaap Interest Expense
InterestExpense
337000
CY2022 us-gaap Interest Expense
InterestExpense
3737000
CY2023 ka Change In Fair Value Of Rights From Private Placement
ChangeInFairValueOfRightsFromPrivatePlacement
1582000
CY2022 ka Change In Fair Value Of Rights From Private Placement
ChangeInFairValueOfRightsFromPrivatePlacement
0
CY2023 ka Gain Loss On Fair Value Measurement Notes Payable
GainLossOnFairValueMeasurementNotesPayable
-22000
CY2022 ka Gain Loss On Fair Value Measurement Notes Payable
GainLossOnFairValueMeasurementNotesPayable
-15280000
CY2023 ka Warrant Expense
WarrantExpense
0
CY2022 ka Warrant Expense
WarrantExpense
3309000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
341000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
99000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
54000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1647000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-21922000
CY2023 us-gaap Profit Loss
ProfitLoss
-14076000
CY2022 us-gaap Profit Loss
ProfitLoss
-63453000
CY2023 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
23000
CY2022 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-45000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-14099000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-63408000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.28
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.28
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-12.87
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-12.87
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11054000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11054000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4926000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4926000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-11949000
CY2022 ka Issuance Of Common Stock Value Upon Extinguishment Of Note Payable
IssuanceOfCommonStockValueUponExtinguishmentOfNotePayable
37519000
CY2022 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
20551000
CY2022 ka Issuance Of Common Stock Value In Connection With Private Placement Net Of Transaction Cost
IssuanceOfCommonStockValueInConnectionWithPrivatePlacementNetOfTransactionCost
7407000
CY2022 ka Issuance Of Warrants To Existing Stockholders
IssuanceOfWarrantsToExistingStockholders
3309000
CY2022 ka Adjustments To Additional Paid In Capital Common Stock Tranche Asset
AdjustmentsToAdditionalPaidInCapitalCommonStockTrancheAsset
2250000
CY2022 ka Issuance Of Warrants In Connection With Convertible Debt Amendments
IssuanceOfWarrantsInConnectionWithConvertibleDebtAmendments
1639000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1581000
CY2022 ka Adjustments To Additional Paid In Capital Note Conversion Discount
AdjustmentsToAdditionalPaidInCapitalNoteConversionDiscount
414000
CY2022 ka Issuance Of Common Stock Value Upon Exercise Of Warrants
IssuanceOfCommonStockValueUponExerciseOfWarrants
71000
CY2022 ka Issuance Of Warrants For Services
IssuanceOfWarrantsForServices
62000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5169000
CY2022 us-gaap Profit Loss
ProfitLoss
-63453000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4570000
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8561000
CY2023 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
189000
CY2023 ka Issuance Of Common Stock Value Upon Exercise Of Warrants
IssuanceOfCommonStockValueUponExerciseOfWarrants
30000
CY2023 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-69000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3854000
CY2023 us-gaap Profit Loss
ProfitLoss
-14076000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3059000
CY2023 us-gaap Profit Loss
ProfitLoss
-14076000
CY2022 us-gaap Profit Loss
ProfitLoss
-63453000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1581000
CY2023 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
30000
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
71000
CY2023 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0
CY2023 ka Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
0
CY2022 ka Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
18860000
CY2023 ka Change In Fair Value Of Rights From Private Placement
ChangeInFairValueOfRightsFromPrivatePlacement
1582000
CY2022 ka Change In Fair Value Of Rights From Private Placement
ChangeInFairValueOfRightsFromPrivatePlacement
0
CY2023 ka Change In Fair Value Of Notes Payable
ChangeInFairValueOfNotesPayable
22000
CY2022 ka Change In Fair Value Of Notes Payable
ChangeInFairValueOfNotesPayable
15280000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
3854000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
5169000
CY2023 ka Warrant Expense
WarrantExpense
0
CY2022 ka Warrant Expense
WarrantExpense
3309000
CY2023 ka Issuance Of Warrants In Connection With Convertible Debt Amendments
IssuanceOfWarrantsInConnectionWithConvertibleDebtAmendments
0
CY2022 ka Issuance Of Warrants In Connection With Convertible Debt Amendments
IssuanceOfWarrantsInConnectionWithConvertibleDebtAmendments
1639000
CY2023 ka Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
739000
CY2022 ka Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
661000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
73000
CY2023 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
189000
CY2022 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
62000
CY2023 us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
0
CY2022 us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
341000
CY2023 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
91000
CY2022 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
62000
CY2023 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-338000
CY2022 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
108000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2941000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-34000
CY2023 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1385000
CY2022 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1694000
CY2023 ka Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-843000
CY2022 ka Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-737000
CY2023 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-442000
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1041000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16209000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19029000
CY2023 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
CY2022 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
9276000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
71000
CY2023 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
331000
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
65000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
331000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9270000
CY2023 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
CY2022 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
7407000
CY2023 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
CY2022 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
6746000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8561000
CY2022 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4000000
CY2023 ka Repayments Of Finance Lease Liabilities
RepaymentsOfFinanceLeaseLiabilities
123000
CY2022 ka Repayments Of Finance Lease Liabilities
RepaymentsOfFinanceLeaseLiabilities
-3000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8468000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11808000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7410000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2049000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13268000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11219000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5858000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13268000
CY2023Q4 us-gaap Cash
Cash
5783000
CY2022Q4 us-gaap Cash
Cash
13143000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
75000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
125000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5858000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13268000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
48000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
2371000
CY2023 us-gaap Stock Issued1
StockIssued1
0
CY2022 us-gaap Stock Issued1
StockIssued1
20551000
CY2023 ka Issuance Of Common Stock Upon Extinguishment Of Notes Payable
IssuanceOfCommonStockUponExtinguishmentOfNotesPayable
0
CY2022 ka Issuance Of Common Stock Upon Extinguishment Of Notes Payable
IssuanceOfCommonStockUponExtinguishmentOfNotesPayable
22239000
CY2023 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
0
CY2022 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
1944000
CY2023 ka Withholding To Cover Taxes From Rsu Vesting
WithholdingToCoverTaxesFromRsuVesting
69000
CY2022 ka Withholding To Cover Taxes From Rsu Vesting
WithholdingToCoverTaxesFromRsuVesting
0
CY2023 us-gaap Payments For Repurchase Of Private Placement
PaymentsForRepurchaseOfPrivatePlacement
0
CY2022 us-gaap Payments For Repurchase Of Private Placement
PaymentsForRepurchaseOfPrivatePlacement
2250000
CY2023 ka Finance Lease Liabilities Arising From Obtaining New Right Of Use Assets
FinanceLeaseLiabilitiesArisingFromObtainingNewRightOfUseAssets
0
CY2022 ka Finance Lease Liabilities Arising From Obtaining New Right Of Use Assets
FinanceLeaseLiabilitiesArisingFromObtainingNewRightOfUseAssets
40000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-165800000
CY2023 us-gaap Profit Loss
ProfitLoss
-14100000
CY2023Q4 us-gaap Cash
Cash
5800000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. These estimates form the basis for judgments the Company makes about the carrying values of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting periods. The Company bases its estimates and judgments on historical experience and on various other assumptions that the Company believes are reasonable under the circumstances. These estimates are based</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">on </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">management’s knowledge about current events and expectations about actions the Company may undertake in the future. These judgments, estimates and assumptions are used for, but not limited to, revenue recognition, accrued research and development expenses, the fair value of notes payable, the fair value of the Company’s common stock prior to the Merger, stock-based compensation, uncertain tax positions and the valuation allowance for net deferred tax assets. Actual results may differ from the Company’s estimates.</span></p>
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially expose the Company to significant concentrations of credit risk consist primarily of cash deposited in accounts at several financial institutions that may exceed federally insured limits. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash to the extent recorded in the consolidated balance sheets. The Company believes it is not exposed to unusual credit risk beyond the normal credit risk associated with commercial banking relationships and has not incurred any such losses to date.</span></p>
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0
CY2023 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.14
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
219000
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
17830000
CY2023 ka Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Change In Notes Payable
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInNotesPayable
22000
CY2022 ka Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Change In Notes Payable
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInNotesPayable
15280000
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
6746000
CY2023 ka Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Change In Debt Extinguishment
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInDebtExtinguishment
0
CY2022 ka Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Change In Debt Extinguishment
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInDebtExtinguishment
673000
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
-4000000
CY2023 ka Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Conversion Of Notes Payable
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesPayable
0
CY2022 ka Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Conversion Of Notes Payable
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesPayable
34964000
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
241000
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
219000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
0
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
866000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
0
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
617000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
249000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
9000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
73000
CY2023 us-gaap Proceeds From Sale Of Foreclosed Assets
ProceedsFromSaleOfForeclosedAssets
240000
CY2023 us-gaap Proceeds From Sale Of Other Assets1
ProceedsFromSaleOfOtherAssets1
331000
CY2022 us-gaap Proceeds From Sale Of Foreclosed Assets
ProceedsFromSaleOfForeclosedAssets
3000
CY2022 us-gaap Proceeds From Sale Of Other Assets1
ProceedsFromSaleOfOtherAssets1
65000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1312000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
745000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
417000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
132000
CY2023Q4 ka Accrued Clinical Trial And Preclinical Costs
AccruedClinicalTrialAndPreclinicalCosts
251000
CY2022Q4 ka Accrued Clinical Trial And Preclinical Costs
AccruedClinicalTrialAndPreclinicalCosts
404000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
97000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2176000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
134000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
70000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2211000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3527000
CY2023Q4 us-gaap Notes Payable
NotesPayable
779000
CY2023Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
770000
CY2022Q4 us-gaap Notes Payable
NotesPayable
779000
CY2022Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
748000
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
620000
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
150000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
748000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
629000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
0
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
0
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
2000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
3000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
145000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
779000
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
620000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
159000
CY2023 us-gaap Debt Conversion Description
DebtConversionDescription
In October 2022 and December 2022, the 2022 convertible notes were amended to provide (i) that the conversion price would be equal to the conversion amount divided by $0.995 upon automatic conversion and (ii) for the issuance of 55,000 warrants to purchase shares of the Company’s non-voting common stock (see Note 9), with exercise contingent upon the Merger closing, including to one investor that was previously a related party (see Note 16), with a fair value of $1.5 million upon issuance.
CY2020Q4 us-gaap Revenues
Revenues
3000000
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
4000000
CY2022 ka Fair Value Of Warrants Issued
FairValueOfWarrantsIssued
21800000
CY2022Q4 ka Non Voting Common Shares Issued
NonVotingCommonSharesIssued
754000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
561000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
14000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
547000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
547000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2023 ka Schedule Of Operating Leases Supplemental Information
ScheduleOfOperatingLeasesSupplementalInformation
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Supplemental information on the Company's operating leases was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:58.257%;"></td> <td style="width:2.679%;"></td> <td style="width:1%;"></td> <td style="width:16.192999999999998%;"></td> <td style="width:1%;"></td> <td style="width:2.679%;"></td> <td style="width:1%;"></td> <td style="width:16.192999999999998%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for operating lease agreement (in thousands)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">936</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">909</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Remaining lease term (in years)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Incremental borrowing rate</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> </table>
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
936000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
909000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y7M6D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y7M6D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2022Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y2M12D
CY2023Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0
CY2022Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.093
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
533000
CY2023 ka Warrant Or Rights Issued
WarrantOrRightsIssued
3688000
CY2023 ka Warrant Or Rights Exercised
WarrantOrRightsExercised
-696000
CY2023 ka Warrant Or Rights Cancelled Or Expired
WarrantOrRightsCancelledOrExpired
-21000
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3504000
CY2023Q4 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
2700000
CY2022Q3 ka Common Stock Warrants Issued
CommonStockWarrantsIssued
2000
CY2022Q3 ka Common Stock Purchased For Professional Services
CommonStockPurchasedForProfessionalServices
62000
CY2022 ka Warrant Expense
WarrantExpense
3300000
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6419000
CY2022Q4 ka Licensing Revenue Agreement Beginning Balance
LicensingRevenueAgreementBeginningBalance
0
CY2021Q4 ka Licensing Revenue Agreement Beginning Balance
LicensingRevenueAgreementBeginningBalance
1041000
CY2023 ka Decrease For Provision Of Research Services
DecreaseForProvisionOfResearchServices
-0
CY2022 ka Decrease For Provision Of Research Services
DecreaseForProvisionOfResearchServices
1041000
CY2023Q4 ka Licensing Revenue Agreement Ending Balance
LicensingRevenueAgreementEndingBalance
0
CY2022Q4 ka Licensing Revenue Agreement Ending Balance
LicensingRevenueAgreementEndingBalance
0
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
442000
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
0
CY2023 ka Increase Due To Acquisition
IncreaseDueToAcquisition
0
CY2022 ka Increase Due To Acquisition
IncreaseDueToAcquisition
442000
CY2023 ka Decrease For Provision Of Researchs Services
DecreaseForProvisionOfResearchsServices
-442000
CY2022 ka Decrease For Provision Of Researchs Services
DecreaseForProvisionOfResearchsServices
0
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
0
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
442000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
734000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
22.67
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y4M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1383000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.19
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
99000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
25.82
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
43000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
16.54
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1975000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M6D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
604000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1072000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
12.8
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
186000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
175000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
26.89
CY2023 ka Share Based Compensations Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released In Period
ShareBasedCompensationsArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod
-159000
CY2023 ka Share Based Compensations Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released Weighted Average Grant Date Fair Value
ShareBasedCompensationsArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue
26.9
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
8000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
26.48
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
8000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
27.14
CY2022Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2900000
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2000000
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-6923000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2000000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
6923000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 ka Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development Tax Credit Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTaxCreditPercent
0.027
CY2022 ka Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development Tax Credit Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTaxCreditPercent
0.008
CY2023 ka Effective Income Tax Rate Reconciliation Debt Fair Value Adjustment
EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustment
0.023
CY2022 ka Effective Income Tax Rate Reconciliation Debt Fair Value Adjustment
EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustment
-0.049
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.142
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.109
CY2023 ka Stock Based Compensation
StockBasedCompensation
-0.067
CY2022 ka Stock Based Compensation
StockBasedCompensation
-0.001
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.024
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.015
CY2023 ka Expiration Of Capital Loss Carryforward
ExpirationOfCapitalLossCarryforward
-0.021
CY2022 ka Expiration Of Capital Loss Carryforward
ExpirationOfCapitalLossCarryforward
0
CY2023 ka Transaction Costs
TransactionCosts
-0.004
CY2022 ka Transaction Costs
TransactionCosts
-0.019
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
-0.044
CY2023 ka Other Net
OtherNet
-0.002
CY2022 ka Other Net
OtherNet
-0.011
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
145232000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
144729000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
22899000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
22384000
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
4409000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
3586000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1807000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1353000
CY2023Q4 ka Deferred Tax Assets Leasing Arrangements
DeferredTaxAssetsLeasingArrangements
115000
CY2022Q4 ka Deferred Tax Assets Leasing Arrangements
DeferredTaxAssetsLeasingArrangements
318000
CY2023Q4 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
19000
CY2022Q4 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
316000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
214000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
103000
CY2023Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
57000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
61000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
174752000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
172850000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
174637000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
172637000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
115000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
213000
CY2023Q4 ka Deferred Tax Liabilities Partnership Basis Deferred
DeferredTaxLiabilitiesPartnershipBasisDeferred
-15000
CY2022Q4 ka Deferred Tax Liabilities Partnership Basis Deferred
DeferredTaxLiabilitiesPartnershipBasisDeferred
-85000
CY2023Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
100000
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
280000
CY2023Q4 us-gaap Deferred Tax Liabilities Other Finite Lived Assets
DeferredTaxLiabilitiesOtherFiniteLivedAssets
0
CY2022Q4 us-gaap Deferred Tax Liabilities Other Finite Lived Assets
DeferredTaxLiabilitiesOtherFiniteLivedAssets
18000
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
115000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
213000
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2000000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
158500000
CY2023Q4 ka Operating Loss Carryforwards Expiration Amount
OperatingLossCarryforwardsExpirationAmount
304200000
CY2023Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
23900000
CY2023 us-gaap Tax Credit Carryforward Limitations On Use
TaxCreditCarryforwardLimitationsOnUse
expire in 2027
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
4400000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3600000
CY2022Q3 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
0.15
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.01
CY2023 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
828000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
630000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
172000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
198000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1000000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
828000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-14099000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-63408000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11054000
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11054000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4926000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4926000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.28
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.28
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-12.87
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-12.87
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4599000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1497000
CY2023 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
115000
CY2022 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
129000
CY2023Q4 ka Percentage Of Workforce Reduction Of Employee
PercentageOfWorkforceReductionOfEmployee
0.64
CY2023 us-gaap Severance Costs1
SeveranceCosts1
246000
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-034676-index-headers.html Edgar Link pending
0000950170-24-034676-index.html Edgar Link pending
0000950170-24-034676.txt Edgar Link pending
0000950170-24-034676-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img147848277_0.jpg Edgar Link pending
img147848277_1.jpg Edgar Link pending
img147848277_10.jpg Edgar Link pending
img147848277_11.jpg Edgar Link pending
img147848277_12.jpg Edgar Link pending
img147848277_13.jpg Edgar Link pending
img147848277_14.jpg Edgar Link pending
img147848277_15.jpg Edgar Link pending
img147848277_16.jpg Edgar Link pending
img147848277_17.jpg Edgar Link pending
img147848277_18.jpg Edgar Link pending
img147848277_19.jpg Edgar Link pending
img147848277_2.jpg Edgar Link pending
img147848277_20.jpg Edgar Link pending
img147848277_21.jpg Edgar Link pending
img147848277_22.jpg Edgar Link pending
img147848277_23.jpg Edgar Link pending
img147848277_24.jpg Edgar Link pending
img147848277_25.jpg Edgar Link pending
img147848277_26.jpg Edgar Link pending
img147848277_27.jpg Edgar Link pending
img147848277_3.jpg Edgar Link pending
img147848277_4.jpg Edgar Link pending
img147848277_5.jpg Edgar Link pending
img147848277_6.jpg Edgar Link pending
img147848277_7.jpg Edgar Link pending
img147848277_8.jpg Edgar Link pending
img147848277_9.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ka-20231231.htm Edgar Link pending
ka-20231231.xsd Edgar Link pending
ka-ex21_1.htm Edgar Link pending
ka-ex23_1.htm Edgar Link pending
ka-ex31_1.htm Edgar Link pending
ka-ex31_2.htm Edgar Link pending
ka-ex32_1.htm Edgar Link pending
ka-ex97_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ka-20231231_htm.xml Edgar Link completed